Access to a new COVID-19 drug will be expanded in low- and middle-income countries following a voluntary licensing agreement between the pharmaceutical company Pfizer and a UN-backed global health initiative, announced in Geneva on Tuesday.
Access to a new COVID-19 drug will be expanded in low- and middle-income countries following a voluntary licensing agreement between the pharmaceutical company Pfizer and a UN-backed global health initiative, announced in Geneva on Tuesday.